{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:29:45Z","timestamp":1773286185311,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.4158\/ep09044.orr1","type":"journal-article","created":{"date-parts":[[2009,6,22]],"date-time":"2009-06-22T21:06:42Z","timestamp":1245704802000},"page":"689-695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Continuous Subcutaneous Pramlintide Infusion Therapy In Patients With Type 1 Diabetes: Observations From A Pilot Study"],"prefix":"10.1016","volume":"15","author":[{"given":"David M.","family":"Huffman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George W.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maighan A.","family":"Seagrove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP09044.ORR1_bb0005","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/00060793-199708000-00006","article-title":"Amylin\u2019s physiology and its role in diabetes","volume":"4","author":"Young","year":"1997","journal-title":"Curr Opin Endocrinol Diab."},{"key":"10.4158\/EP09044.ORR1_bb0010","series-title":"SYMLIN (pramlintide acetate) injection. Prescribing information","year":"2005"},{"key":"10.4158\/EP09044.ORR1_bb0015","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/meta.2002.32022","article-title":"The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes","volume":"51","author":"Fineman","year":"2002","journal-title":"Metabolism."},{"key":"10.4158\/EP09044.ORR1_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/diacare.26.1.1","article-title":"Impact of pramlin- tide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps","volume":"26","author":"Levetan","year":"2003","journal-title":"Diabetes Care."},{"key":"10.4158\/EP09044.ORR1_bb0025","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s00125-005-1732-4","article-title":"Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes","volume":"48","author":"Chapman","year":"2005","journal-title":"Diabetologia."},{"key":"10.4158\/EP09044.ORR1_bb0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/dmrr.419","article-title":"Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study","volume":"20","author":"Maggs","year":"2004","journal-title":"Diabetes Metab Res Rev."},{"key":"10.4158\/EP09044.ORR1_bb0035","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.2337\/diacare.26.11.3074","article-title":"Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study","volume":"26","author":"Weyer","year":"2003","journal-title":"Diabetes Care."},{"key":"10.4158\/EP09044.ORR1_bb0040","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a one-year, randomized controlled trial","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabet Med."},{"key":"10.4158\/EP09044.ORR1_bb0045","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2337\/dc06-0042","article-title":"A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes","volume":"29","author":"Edelman","year":"2006","journal-title":"Diabetes Care."},{"key":"10.4158\/EP09044.ORR1_bb0050","series-title":"Amylin Physiology and Pharmacology","first-page":"52","author":"Young","year":"2005"},{"key":"10.4158\/EP09044.ORR1_bb0055","doi-asserted-by":"crossref","first-page":"644","DOI":"10.2337\/diab.19.9.644","article-title":"Mean amplitude of glycemic excursions, a measure of diabetic instability","volume":"19","author":"Service FJ","year":"1970","journal-title":"Diabetes."},{"key":"10.4158\/EP09044.ORR1_bb0060","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1089\/dia.2006.8.644","article-title":"A novel analytical method for assessing glucose variability: using CGMS in type 1 diabetes mellitus","volume":"8","author":"McCall","year":"2006","journal-title":"Diabetes Technol Ther."},{"key":"10.4158\/EP09044.ORR1_bb0065","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2337\/dc06-1026","article-title":"Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes","volume":"30","author":"Marrero","year":"2007","journal-title":"Diabetes Care."},{"key":"10.4158\/EP09044.ORR1_bb0070","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1463-1326.2004.00417.x","article-title":"The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes","volume":"7","author":"Amiel","year":"2005","journal-title":"Diabetes Obes Metab."},{"issue":"suppl 2","key":"10.4158\/EP09044.ORR1_bb0075","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1002\/(SICI)1096-9136(199706)14:2+<S19::AID-DIA400>3.0.CO;2-4","article-title":"Effect of amylin and the amylin agonist pramlintide on glucose metabolism","volume":"14","author":"Schmitz","year":"1997","journal-title":"Diabet Med."},{"key":"10.4158\/EP09044.ORR1_bb0080","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2337\/diacare.21.6.987","article-title":"Pearson L, Schoenfeld SL, Kolterman OG (Pramlintide in Type 2 Diabetes Group). Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin","volume":"21","author":"Thompson","year":"1998","journal-title":"Diabetes Care."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20415563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20415563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/R26010Q3N43NM348.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:50:10Z","timestamp":1761515410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20415563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S1530891X20415563"],"URL":"https:\/\/doi.org\/10.4158\/ep09044.orr1","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Continuous Subcutaneous Pramlintide Infusion Therapy In Patients With Type 1 Diabetes: Observations From A Pilot Study","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP09044.ORR1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}